URGENT: This Altcoin Opportunity Won’t Wait – Act Now

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

VACC Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Notice: This stock is marked as potentially delisted. It may not be actively trading.

Insider Ownership Percentage: 6.00%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

Vaccitech Insider Trading History Chart

Vaccitech Share Price & Price History

^$0.92

▼ -0.05 (-5.14%)

As of 12/17/2024 01:00 AM ET

URGENT: This Altcoin Opportunity Won’t Wait – Act Now

From Crypto Swap Profits | Ad

It’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life-changing for those who are prepared. Why? Because altcoin prices are about to explode.

>> Register for the Workshop Now

Vaccitech Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/26/2023	Joseph Scheeren	Director	Buy	10,000	$2.44	$24,400.00	23,000
5/25/2023	Robin Wright	Director	Buy	13,750	$2.66	$36,575.00	48,256
3/27/2023	William Enright	CEO	Sell	15,000	$2.42	$36,300.00	728,454
8/25/2022	Graham Griffiths	Insider	Sell	10,000	$7.39	$73,900.00	104,209
8/24/2022	Christopher Ellis	COO	Sell	450	$4.78	$2,151.00	75
8/18/2022	Christopher Ellis	COO	Sell	2,175	$4.84	$10,527.00	75
8/17/2022	Graham Griffiths	Insider	Sell	500	$4.76	$2,380.00	114,209
8/12/2022	Graham Griffiths	Insider	Sell	5,000	$4.50	$22,500.00	118,329
6/28/2022	Christopher Ellis	COO	Sell	5	$6.00	$30.00	75
6/23/2022	Graham Griffiths	Insider	Sell	8	$5.28	$42.24	123,229
4/1/2022	Joseph Scheeren	Director	Buy	10,000	$5.09	$50,900.00	3,000
12/22/2021	Robin Wright	Director	Buy	10,000	$9.97	$99,700.00

Uncover the Top Gold Stock of the Bull Market

From Huge Alerts | Ad

Gold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?

Click here to see how this opportunity could transform your portfolio.

SEC Filings (Institutional Ownership Changes) for Vaccitech (NASDAQ:VACC)

26.13% of Vaccitech stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Vaccitech Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
5/10/2024	M&G Plc	5,197,349	$25.99M	0.2%	N/A	13.483%
1/31/2024	Ipswich Investment Management Co. Inc.	23,075	$0.12M	0.0%	-14.8%	0.060%
11/8/2023	Janney Montgomery Scott LLC	15,008	$46K	0.0%	N/A	0.039%
5/15/2023	Liontrust Investment Partners LLP	455,848	$1.02M	0.0%	-24.0%	1.189%
4/24/2023	Ipswich Investment Management Co. Inc.	27,075	$61K	0.0%	+26.7%	0.071%
11/16/2022	Alphabet Inc.	1,513,644	$4.84M	0.2%	N/A	4.058%
11/1/2022	M&G Investment Management Ltd.	5,197,349	$15.59M	0.1%	+377.4%	13.964%
10/11/2022	Ipswich Investment Management Co. Inc.	23,475	$75K	0.0%	-41.3%	0.063%
7/26/2022	Ipswich Investment Management Co. Inc.	39,975	$0.18M	0.1%	-23.7%	0.107%
2/14/2022	Johns Hopkins University	107,968	$1.20M	0.1%	N/A	0.310%
2/14/2022	ETF Managers Group LLC	10,087	$0.11M	0.0%	-21.9%	0.029%
11/22/2021	Liontrust Investment Partners LLP	600,000	$9.44M	0.1%	N/A	1.720%
11/16/2021	Brookfield Asset Management Inc.	15,921	$0.25M	0.0%	-36.3%	0.046%
11/15/2021	Tudor Investment Corp Et Al	378,260	$5.73M	0.0%	-10.0%	1.102%
11/15/2021	Caas Capital Management LP	10,251	$0.16M	0.0%	-79.5%	0.030%
11/12/2021	Ghisallo Capital Management LLC	20,625	$0.33M	0.0%	+106.3%	0.060%
10/7/2021	Ipswich Investment Management Co. Inc.	51,475	$0.81M	0.2%	+18.9%	0.150%
8/23/2021	DC Funds LP	642,204	$10.78M	51.2%	N/A	1.871%
8/17/2021	Brookfield Asset Management Inc.	25,000	$0.42M	0.0%	N/A	0.073%
8/17/2021	Millennium Management LLC	130,137	$2.18M	0.0%	N/A	0.379%
8/17/2021	Caas Capital Management LP	50,000	$0.84M	0.0%	N/A	0.146%
8/16/2021	Squarepoint Ops LLC	25,000	$0.42M	0.0%	N/A	0.073%
8/16/2021	M&G Investment Management Ltd.	1,088,597	$18.51M	0.0%	N/A	3.171%
8/16/2021	Cubist Systematic Strategies LLC	11,562	$0.19M	0.0%	N/A	0.034%
8/16/2021	Tudor Investment Corp Et Al	420,319	$6.02M	0.1%	N/A	1.224%
8/12/2021	Monashee Investment Management LLC	132,184	$2.22M	0.3%	N/A	0.385%
8/11/2021	Arena Capital Advisors LLC CA	30,698	$0.52M	0.0%	N/A	0.089%

Data available starting January 2016

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.

Today's Range

Now: $0.92

$0.90

$1.05

50 Day Range

MA: $1.57

$1.19

$5.00

52 Week Range

Now: $0.92

$1.64

$5.10

Volume

72,492 shs

Average Volume

244,643 shs

Market Capitalization

$35.58 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Vaccitech?: Vaccitech's top insider shareholders include:
William Enright (CEO)
Robin Wright (Director)
Joseph Scheeren (Director)
Learn More about top insider investors at Vaccitech.

URGENT: This Altcoin Opportunity Won’t Wait – Act Now

From Crypto Swap Profits | Ad

VACC Insider Trading

Vaccitech Insider Trading History Chart

Vaccitech Share Price & Price History

Vaccitech Insider Trading History

SEC Filings (Institutional Ownership Changes) for Vaccitech (NASDAQ:VACC)

Institutional Buying and Selling by Quarter

Vaccitech Institutional Trading History

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Who are the company insiders with the largest holdings of Vaccitech?